Title:
SELECTIVE BCL-XL PROTAC COMPOUNDS AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/078581
Kind Code:
A1
Abstract:
The present application relates to novel PROTAC compounds, and tautomers, stereoisomers, or pharmaceutically acceptable salts thereof, which degrade and/or inhibit the level or activity of BCL-XL proteins. The present application also relates to pharmaceutical compositions comprising one or more of the PROTAC compounds and tautomers, stereoisomers, or pharmaceutically acceptable salts thereof as an active ingredient, and to the use of the PROTAC compounds and tautomers, stereoisomers, or pharmaceutically acceptable salts thereof in the treatment of BCL-XL associated diseases, disorders or conditions, including cancers.
Inventors:
PAN ZHENGYING (CN)
Application Number:
PCT/CN2023/124262
Publication Date:
April 18, 2024
Filing Date:
October 12, 2023
Export Citation:
Assignee:
APPICINE THERAPEUTICS HK LTD (CN)
International Classes:
C07D471/04; A61K31/635; A61P35/00
Attorney, Agent or Firm:
JUN HE LAW OFFICES (CN)
Download PDF: